EAPH-07. CHILDREN’S BRAIN TUMOUR DRUG DELIVERY CONSORTIUM

There is an urgent need to expedite the development of new or repurposed drugs for children’s cancer. An additional challenge in the developing brain is to ensure the drug is delivered to the tumour at therapeutic and non-toxic concentrations for sufficient duration to achieve the biological effect. Children’s brain tumours account for over 20% of childhood cancers and differ significantly in their biological characteristics from their adult counterparts